The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment
Abstract
BACKGROUND: The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely among individuals. Plasma concentrations of the active tamoxifen metabolite endoxifen are associated with the cytochrome P450 (CYP) 2D6 genotype. We examined the effects of concomitant use of selective serotonin reuptake inhibitor antidepressants, which are CYP2D6 enzyme inhibitors commonly prescribed to treat hot flashes in women who take tamoxifen, and genotypes for genes that encode tamoxifen-metabolizing enzymes on plasma concentrations of tamoxifen and its metabolites. METHODS: Eighty patients with newly diagnosed with breast cancer who were beginning tamoxifen therapy (20 mg/day orally), 24 of whom were taking CYP2D6 inhibitors, were genotyped for common alleles of the CYP2D6, CYP2C9, CYP3A5, and sulfotransferase (SULT) 1A1 genes. Plasma concentrations of tamoxifen and its metabolites were measured after 1 and 4 months of tamoxifen therapy. Differences in plasma concentrations of tamoxifen and its metabolites between genotype groups were analyzed by the Wilcoxon rank sum test. All statistical tests were two-sided. RESULTS: Among all women, plasma endoxifen concentrations after 4 months of tamoxifen therapy were statistically significantly lower in subjects with a CYP2D6 homozygous variant genotype (20.0 nM, 95% confidence interval [CI] = 11.1 to 28.9 nM) or a heterozygous genotype (43.1 nM, 95% CI = 33.3 to 52.9 nM) than in those with a homozygous wild-type genotype (78.0 nM, 95%CI = 65.9 to 90.1 nM) (both P = .003). Among subjects who carried a homozygous wild-type genotype, the mean plasma endoxifen concentration for those who were using CYP2D6 inhibitors was 58% lower than that for those who were not (38.6 nM versus 91.4 nM, difference = -52.8 nM, 95% CI = -86.1 to -19.5 nM, P = .0025). The plasma endoxifen concentration was slightly reduced in women taking venlafaxine, a weak inhibitor of CYP2D6, whereas the plasma endoxifen concentration was reduced substantially in subjects who took paroxetine (a potent inhibitor of CYP2D6). Genetic variations of CYP2C9, CYP3A5, or SULT1A1 had no statistically significant associations with plasma concentrations of tamoxifen or its metabolites. CONCLUSION: Interactions between CYP2D6 polymorphisms and coadministered antidepressants and other drugs that are CYP2D6 inhibitors may be associated with altered tamoxifen activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Nonparametric Statistical Methods.
Knott, M., Hollander, M., & Wolfe, D. A. (1974) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344557 · Cited by 2,662
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Self-citationCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Self-citationHolmberg, L., & Anderson, H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15493-7 · Cited by 533
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Stearns, V., Beebe, K. L., Iyengar, M., & Dube, E. (2003) · JAMA · doi:10.1001/jama.289.21.2827 · Cited by 496
Self-citationAntiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Self-citationPhase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
Stearns, V., Ullmer, L., Lopez, J. F., Smith, Y., Isaacs, C., & Hayes, D. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11774-0 · Cited by 354
Self-citationVenlafaxine oxidation in vitro is catalysed by CYP2D6
OTTON, S. V., BALL, S. E., CHEUNG, S. W., INABA, T., RUDOLPH, R. L., & SELLERS, E. M. (1996) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1996.tb00173.x · Cited by 227
Crewe, H. K., Ellis, S. W., Lennard, M. S., & Tucker, G. T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00650-8 · Cited by 223
Genetic analysis of CYP2C9 polymorphism in a Japanese population
Nasu, K., Kubot, T., & Ishizaki, T. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00011 · Cited by 185
Gaedigk, A., Gotschall, R. R., Forbes, N. S., Simon, S. D., Kearns, G. L., & Leeder, J. S. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199912000-00002 · Cited by 181
Hersberger, M., Marti-Jaun, J., Rentsch, K., & Hänseler, E. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.8.1072 · Cited by 164
Desta, Z., Kerbusch, T., & Flockhart, D. A. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70117-7 · Cited by 129
Self-citationCoughtrie, M. W. H., Gilissen, R., Benedicte, S. H. E. K., Strange, R. C., Fryer, A. A., Jones, P. W., & Bamber, D. E. (1998) · Biochemical Journal · doi:10.1042/bj3370045 · Cited by 128
Pezzella, G., Moslinger-Gehmayr, R., & Contu, A. S. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1012518831494 · Cited by 119
Owen, J. R., & Nemeroff, C. B. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+<24::aid-da7>3.0.co;2-f · Cited by 86
Winer, E. P., Hudis, C. A., Burstein, H. J., Bryant, J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gelber, R. D., Gralow, J. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.596 · Cited by 83
DeCensi, A., Gandini, S., Guerrieri‐Gonzaga, A., Johansson, H. A., Manetti, L., Bonanni, B., Sandri, M. T., Barreca, A., Costa, A., Robertson, C., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2633 · Cited by 79
Multiple Comparisons and Multiple Tests
Ziegel, E. R., Westfall, P. H., Tobias, R. D., Rom, D., Wolfinger, R. D., & Hochberg, Y. (2000) · Technometrics · doi:10.1080/00401706.2000.10486077 · Cited by 58
Fried, K. M., & Wainer, I. W. (1994) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(94)00054-9 · Cited by 54
4‐Hydroxytamoxifen sulfation metabolism
Chen, G., Yin, S., Maiti, S., & Shao, X. (2002) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.10048 · Cited by 41
Bang, L. M., & Keating, G. M. (2004) · CNS Drugs · doi:10.2165/00023210-200418060-00003 · Cited by 26
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Metadata
- Authors
- Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., Blanchard, R., Nguyen, A., Ullmer, L., Hayden, J., Lemler, S., Weinshilboum, R. M., Rae, J. M., Hayes, D. F., & Flockhart, D. A.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-04
- Volume
- 97
- Issue
- 1
- Pages
- 30-39
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2047246104
- Cited by
- 951
- References
- 28
- FWCI
- 49.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.